AnGes, Inc. (AJW.F)
- Previous Close
0.2360 - Open
0.2340 - Bid --
- Ask 0.3560 x 114000
- Day's Range
0.2340 - 0.2360 - 52 Week Range
0.2340 - 0.9400 - Volume
1 - Avg. Volume
0 - Market Cap (intraday)
59.069M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.
www.anges.co.jpRelated News
Performance Overview: AJW.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AJW.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AJW.F
Valuation Measures
Market Cap
59.07M
Enterprise Value
36.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
51.11
Price/Book (mrq)
0.30
Enterprise Value/Revenue
0.24
Enterprise Value/EBITDA
-0.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.09%
Return on Equity (ttm)
-26.31%
Revenue (ttm)
152M
Net Income Avi to Common (ttm)
-7.44B
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.16B
Total Debt/Equity (mrq)
1.38%
Levered Free Cash Flow (ttm)
-9.18B
Company Insights: AJW.F
AJW.F does not have Company Insights